Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 326 - 350 of 11571 in total

Iloprost

Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived. Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported...
Approved
Investigational
Matched Description: … [A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately ... [L50146] It is a potent vasodilator with reported anti-thrombotic properties. …

Dapagliflozin

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron...
Approved
Matched Description: … Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor …

Cefdinir

Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to...
Approved
Matched Description: … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third ... Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially …

Difluocortolone

Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Approved
Investigational
Withdrawn
Matched Iupac: … hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … Difluocortolone is a potent topical corticosteroid. …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody …

Chloroxylenol

Chloroxylenol, or para-chloro-meta-xylenol (PCMX), is an antiseptic and disinfectant agent used for skin disinfection and surgical instruments. It is found in antibacterial soaps, wound-cleansing applications, and household antiseptics. The halophenol is shown to be most effective against Gram positive bacteria where it disrupts the cell wall due to its phenolic...
Approved
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Products: … Germ A Stat …

Aprocitentan

Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker,...
Approved
Investigational
Matched Description: … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension ... renin-angiotensin system blocker, a calcium channel blocker, and a diuretic at maximally tolerated doses ... have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a …

Sarilumab

Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to ... [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been …

Miconazole

Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027,...
Approved
Investigational
Vet approved
Matched Description: … Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as ... including both oral and vaginal infections; although intravenous miconazole is no longer available, a ... [A214523, L14021] It is currently available as a variety of prescription and over the counter products …

Isocarboxazid

Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription...
Approved
Matched Description: … It is a monoamine oxidase inhibitor. ... introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a …
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …

Lactic acid

A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as...
Approved
Vet approved
Matched Description: … A normal intermediate in the fermentation (oxidation, metabolism) of sugar. ... resulting lactic acid to create a compound having the formula NaC3H5O3. ... (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste …
Matched Mixtures name: … PERI SOLUTION A ... Delflex A Perit.dial.solN.W.1.5%dext.low mg ... Delflex A Perit.dial.solN.W.2.5%dext.low mg …

Casimersen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Matched Description: … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) ... Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of ... morpholino ring, and the phosphodiester links between nucleotides are replaced with a phosphorodiamidate …

Pargyline

Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Approved
Matched Description: … Pargyline is a monoamine oxidase inhibitor with antihypertensive properties. …
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …

Peginesatide

Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide...
Approved
Investigational
Matched Description: … Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. ... Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from ... Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Futibatinib

Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed...
Approved
Investigational
Matched Description: … Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor ... tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival ... FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated …

Efgartigimod alfa

Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction. The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in...
Approved
Investigational
Matched Description: … common pathophysiological mechanisms behind MG, and results in the destruction of these receptors and a ... L39496] IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a ... [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor …

Piperonyl butoxide

Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist. It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as...
Approved
Vet approved
Matched Description: … Piperonyl butoxide is a synergist. ... Piperonyl butoxide is a semisynthetic derivative of safrole. ... Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. …
Matched Mixtures name: … Mata Piojos A Pediculicide Low Foaming …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Bismuth subsalicylate

Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of salicylic acid linked to trivalent bismuth cation. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth subsalicylate has been around for over 100 years: it...
Approved
Vet approved
Matched Description: … [A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that ... ], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ for ... [L32318] Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole …

Topotecan

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Approved
Investigational
Matched Categories: … MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Ajmaline

An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very...
Approved
Experimental
Matched Description: … Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a ... It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac ... It has also been used for many years as a drug to challenge the conduction system of the heart in cases …

Radium Ra 223 dichloride

Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was...
Approved
Investigational
Matched Description: … As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas ... Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short ... The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant …

Danicopan

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis ... in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a ... [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks …

Peginterferon alfa-2a

Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Investigational
Matched Description: … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... Use of Peginterferon alfa-2a is associated with a wide range of severe adverse effects including the …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Oxcarbazepine

Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of carbamazepine and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate...
Approved
Matched Description: … [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of ... its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood ... - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the …

Adagrasib

Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Description: … high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a ... [A254052] In a phase I/IB clinical study that included patients with KRASG12C-mutated advanced ... [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib …
Displaying drugs 326 - 350 of 11571 in total